Call for Special Issue Proposals
Carcinogenesis invites proposals for special issues that highlight emerging areas of cancer research and integrate discoveries across molecular, cellular, translational, and population sciences. Special Issues provide an opportunity to bring together leading investigators to synthesize advances and define future directions in rapidly evolving areas of carcinogenesis research.
Editor-in-Chief:
Dr Sharon R. Pine, PhD
Section Editors:
Tatsuhiro Shibata
Theo Mantamadiotis
Editorial Board
-
3.82025 Impact Factor
-
6.12025 CiteScore

Why Publish with Carcinogenesis?
Carcinogenesis: Integrative Cancer Research is a multi-disciplinary journal that brings together all the varied aspects of research that will ultimately lead to the prevention of cancer in humans.
Find out more about the benefits of publishing with us here.

Meet the Editor-in-Chief
Dr. Sharon Pine, PhD, is a Professor in the Department of Medicine, Division of Medical Oncology at the University of Colorado School of Medicine, the Pia and Fred R. Hirsch Endowed Chair in Lung Cancer Research, and Director of the Thoracic Oncology Research Initiative (TORI) at the University of Colorado Comprehensive Cancer Center.
Read and Publish Agreements
OUP has a growing number of Read and Publish agreements with institutions and consortia which provide funding for open access publishing. This means authors from participating institutions can publish open access, and the institution may pay the charge.
Find out if your institution is participating here

Editor's Choice
These articles have been hand-picked by Editor-in-Chief, Dr. Sharon Pine, to showcase some of the outstanding research published in Carcinogenesis.
Read more here

Carcinogenesis Outstanding Scientist Award
The Editors of Carcinogenesis have awarded Dr. Lorne J. Hofseth the first Carcinogenesis Outstanding Scientist Award for his paper, “Allura Red AC is a xenobiotic. Is it also a carcinogen?” and his contributions to the field and the journal. Dr. Hofseth’s research exemplifies the scientific excellence, clarity, and influence that the award is intended to recognize.

Carcinogenesis and Web of Science Reviewer Recognition
Carcinogenesis partners with Web of Science Reviewer Recognition to recognise our expert peer reviewers and raise the status of peer review.
Find out more here.

Ready to submit?
Learn how to publish your next paper with Carcinogenesis.
Find out more about the policies for the required Data Availability Statements and, for Cell lines used, Cell line Authentication.

Carcinogenesis First‑time Author Recognition
Carcinogenesis is pleased to introduce a new initiative to recognise first‑time authors: authors who are a) listed as first author on a paper and b) publishing for the first time may be highlighted through our communications channels to help bring wider visibility to their work.
Discover our first-time authors and their papers
NAMPT orchestrates immune evasion and stromal remodeling in the tumor microenvironment. This review maps its context-dependent functions across immune and stromal compartments and spotlights next-generation strategies that could finally deliver safe, effective NAMPT-targeted therapy.
Growing epidemiological evidence indicates that dietary fats and obesity are linked to prostate cancer (PCa) progression. This study examines the impact of a lard-based diet (LD) on PCa progression through gut microbiota alterations and immune modulation. Using a prostate-specific Pten knockout ...
Aberrant glucose metabolism is a hallmark of cancer metabolic reprogramming. The mitochondrial pyruvate dehydrogenase complex (PDC) acts as a central metabolic node that converts pyruvate into acetyl-CoA to sustain oxidative phosphorylation (OXPHOS). In tumor cells, however, overexpressed pyruvate ...
Cancer is conventionally defined when malignant transformation can be demonstrated, yet carcinogenesis is increasingly understood as a multistep biological process extending from exposure and tissue response through clonal evolution and, in some individuals, clinically apparent malignancy. The ...
Exercise reduces colorectal cancer risk, but its protective mechanisms in early carcinogenesis remain unclear. Male C57BL/6 mice (n = 10/group) were used in two experimental designs: (i) an acute molecular and epigenetic study to evaluate early changes 8h and 24h after a single Azoxymethane (AOM) ...
This year marks the 80th anniversary of the atomic bombings of Hiroshima and Nagasaki. Over the past eight decades, large-scale cohort studies of atomic bomb survivors and their offspring conducted by the Radiation Effects Research Foundation and its predecessor, the Atomic Bomb Casualty Commission, have provided critical ...
Plastics have become integral to modern life, but their persistence has generated vast quantities of microplastics (MPs, <5 mm) and nanoplastics (NPs, <1 µm) that now contaminate food, water, air, and human tissues. Although not yet classified as carcinogens by the International Agency for Research on Cancer, ...
This paper concludes the third comprehensive report on radiation effects on solid cancer incidence within the Life Span Study (LSS) cohort of Japanese atomic bomb survivors, adding 11 years of follow-up. Over 1958–2009, 22 538 solid cancer cases and 3.1 million person-years were identified among 105 444 individuals. The ...
Considering carcinogenic risk for vapers in comparison with never-users, findings 2017–25 from all types of investigation record increasing concern and taken together indicate that nicotine-containing e-cigarettes are likely to be carcinogenic to humans causing lung cancer and oral cancer.
Interleukin 17 (IL17) is a cytokine involved in diverse immune responses. Its role in different cancer subtypes remains unknown. This systematic review provides novel insights into IL17’s oncogenic roles in various malignancies.
SMARCA4-deficient ccRCC exhibit increased OXPHOS capacity paired with heightened energy consumption for biosynthesis. Notably, we identified OXPHOS as a therapeutically exploitable vulnerability in SMARCA4-deficient ccRCC, demonstrating the potent and distinct antitumor efficacy of the small molecule IACS-010759 in these tumors.
Given the strong heterogeneity of TNBC, personalized treatment is essential for patients. This review outlines the classification strategies and IHC markers for TNBC subtypes, and detection targets for targeted drug indications, aiming to support individualized treatment strategies for TNBC patients.
This review focuses on their mechanisms, including secreting inhibitory factors, regulating immune cells, and affecting antigen presentation, aiming to provide insights into anti-cancer strategies.
